ERBB2 and breast carcinoma: In 2013, T-DM1 was approved as a single therapy for the treatment of advanced-stage HER2-positive early breast cancer (EBC) after neoadjuvant treatment with trastuzumab and a taxane (paclitaxel or docetaxel) [19].